Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PS18
- Development stage
- Preclinical
- Lead developer
- Givaudan
- Modality
- Peptides
- Administration
- Intracerebroventricular
01
Overview
PS18 is a prosaposin-derived 18-mer peptide analog that exhibits neurotrophic and anti-apoptotic properties. It has been shown to reduce neuronal damage and apoptosis, particularly by antagonizing endoplasmic reticulum (ER) stress. In models of Parkinson's disease, PS18 significantly reduced dopaminergic neuronal loss and ER stress markers such as PERK, ATF6, CHOP, and BiP, suggesting a neuroprotective role. Its mechanism of action involves mitigating ER stress, which is implicated in neurodegenerative processes.
- Other names
- prosaposin-derived 18-mer peptideprosaposin-derived18-mer peptideprosaposin-derived-18-mer peptide
02
Targets
ATF6 (Activating transcription factor 6 alpha)DDIT3 (DNA damage-inducible transcript 3 protein)EIF2AK3 (Pkr-like endoplasmic reticulum kinase)HSPA5 (Heat shock protein family A member 5)
Beyond the preview
Go deeper on PS18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PS18.